期刊
ISCIENCE
卷 25, 期 11, 页码 -出版社
CELL PRESS
DOI: 10.1016/j.isci.2022.105458
关键词
-
资金
- Department of Defense's Congressionally Directed Medical Research Program on Tuberous Sclerosis Complex [W81XWH-18-1-0370]
- NIH [P01-CA120964, R35CA197459, T32-ES016645]
- NCI Cancer Center [NIH 5 P30 CA06516]
mTORC1 activation in cancer and TSC leads to cellular dependence on pro-survival proteins. Inhibiting mTORC1 alters this dependence, making cells more susceptible to apoptosis-inducing drugs.
mTORC1 is aberrantly activated in cancer and in the genetic tumor syndrome tuberous sclerosis complex (TSC), which is caused by loss-of-function mutations in the TSC complex, a negative regulator of mTORC1. Clinically approved mTORC1 inhibitors, such as rapamycin, elicit a cytostatic effect that fails to eliminate tumors and is rapidly reversible. We sought to determine the effects of mTORC1 on the core regulators of intrinsic apoptosis. In TSC2-deficient cells and tumors, we find that mTORC1 inhibitors shift cellular dependence from MCL-1 to BCL-2 and BCL-X-L for survival, thereby altering susceptibility to BH3 mimetics that target specific pro-survival BCL-2 proteins. The BCL-2/BCL-X-L inhibitor ABT-263 synergizes with rapamycin to induce apoptosis in TSC-deficient cells and in a mouse tumor model of TSC, resulting in a more complete and durable response. These data expose a therapeutic vulnerability in regulation of the apoptotic machinery downstream of mTORC1 that promotes a cytotoxic response to rapamycin.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据